OTC醫藥品產業：BRIC各國（巴西•俄羅斯•印度•中國）的產業指南 是由出版商MarketLine在2010年11月所出版的。
這份英文市場調查報告書包含Pages: 153 價格從美金995起跳。
Abstract
Datamonitor' s OTC Pharmaceuticals - BRIC (Brazil, Russia, India, China)
Industry Guide is an essential resource for top-level data and analysis
covering the BRIC (Brazil, Russia, India, China) OTC Pharmaceuticals industry.
The report includes easily comparable data on market value, volume,
segmentation and market share, plus full five year market forecasts. It
examines future problems, innovations and potential growth areas within the
market.
Scope of the Report
* Contains an executive summary and data on value, volume and
segmentation
* Provides textual analysis of the industry' s prospects, competitive
landscape and profiles of the leading companies
* Incorporates in-depth five forces competitive environment analysis and
scorecards
* Compares data from Brazil, Russia, India, and China, alongside individual
chapters on each country. .
* Includes a five-year forecast of the industry
Highlights
The BRIC OTC Pharmaceuticals market grew by 7.2% between 2005 and 2009to reach
a value of $19640.4 million.
In 2014, the market is forecast to have a value of $26980 million, an increase
of 6.6% from 2009.
Brazil was the fastest growing country with a CAGR of 8.2% over the
2005-09 period.
Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research
Market Definition
The OTC pharmaceuticals market consists of the retail sale of traditional
medicines, cough and cold preparations (tablets, mixtures, lozenges, topical
remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals,
single vitamins, tonics, cod liver oil), indigestion preparations (tablets,
powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other
analgesics), and medicated skin products (anti-bacteria’s, acne
treatments, anti-fungal, disinfectants and other), topical OTC medicines
(anesthetic products, anti-itch products, antibiotic creams/gels), plasters &
bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze,
liquid bandages and other tape or bandage), first aid kits and other
(anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and
motion sickness).
Table of Contents
TABLE OF CONTENTS
ABOUT DATAMONITOR
INTRODUCTION
What is this report about?
Who is the target reader?
How to use this report
Definitions
BRIC OTC Pharmaceuticals Outlook
OTC Pharmaceuticals in Brazil
Market overview
Market value
Market segmentation I
Market segmentation II
Market share
Five forces analysis
Leading companies
Market distribution
Market forecasts
Macroeconomic indicators
OTC Pharmaceuticals in China
Market overview
Market value
Market segmentation I
Market segmentation II
Market share
Five forces analysis
Leading companies
Market distribution
Market forecasts
Macroeconomic indicators
OTC Pharmaceuticals in India
Market overview
Market value
Market segmentation I
Market segmentation II
Market share
Five forces analysis
Leading companies
Market distribution
Market forecasts
Macroeconomic indicators
OTC Pharmaceuticals in Russia
Market overview
Market value
Market segmentation I
Market segmentation II
Market share
Five forces analysis
Leading companies
Market distribution
Market forecasts
Macroeconomic indicators
Appendix
Data Research Methodology
LIST OF TABLES
Table 1: BRIC OTC pharmaceuticals industry, revenue($m), 2005-14
Table 2: BRIC OTC pharmaceuticals industry, revenue($m), 2005-09
Table 3: BRIC OTC pharmaceuticals industry, revenue($m, 2009-14
Table 4: Brazil otc pharmaceuticals market value: $ million, 2005-09
Table 5: Brazil otc pharmaceuticals Market segmentation I:% share, by value,
2009
Table 6: Brazil otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Table 7: Brazil otc pharmaceuticals market share: % share, by value, 2009
Table 8: Johnson & Johnson: key facts
Table 9: Johnson & Johnson: key financials ($)
Table 10: Johnson & Johnson: key financial ratios
Table 11: Sanofi-Aventis: key facts
Table 12: Sanofi-Aventis: key financials ($)
Table 13: Sanofi-Aventis: key financials (€)
Table 14: Sanofi-Aventis: key financial ratios
Table 15: Abbott Laboratories: key facts
Table 16: Abbott Laboratories: key financials ($)
Table 17: Abbott Laboratories: key financial ratios
Table 18: Brazil otc pharmaceuticals market distribution: % share, by value,
2009
Table 19: Brazil OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 20: Brazil size of population (million), 2005-09
Table 21: Brazil gdp (constant 2000 prices, $ billion), 2005-09
Table 22: Brazil gdp (current prices, $ billion), 2005-09
Table 23: Brazil inflation, 2005-09
Table 24: Brazil consumer price index (absolute), 2005-09
Table 25: Brazil exchange rate, 2005-09
Table 26: China otc pharmaceuticals market value: $ million, 2005-09
Table 27: China otc pharmaceuticals Market segmentation I:% share, by value,
2009
Table 28: China otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Table 29: China otc pharmaceuticals market share: % share, by value, 2009
Table 30: Johnson & Johnson: key facts
Table 31: Johnson & Johnson: key financials ($)
Table 32: Johnson & Johnson: key financial ratios
Table 33: Novartis AG: key facts
Table 34: Novartis AG: key financials ($)
Table 35: Novartis AG: key financial ratios
Table 36: Chengdu Rosun Antiseptic Pharmaceutical Co., Ltd: key facts
Table 37: China otc pharmaceuticals market distribution: % share, by value,
2009
Table 38: China OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 39: China size of population (million), 2005-09
Table 40: China gdp (constant 2000 prices, $ billion), 2005-09
Table 41: China gdp (current prices, $ billion), 2005-09
Table 42: China inflation, 2005-09
Table 43: China consumer price index (absolute), 2005-09
Table 44: China exchange rate, 2005-09
Table 45: India otc pharmaceuticals market value: $ million, 2005-09
Table 46: India otc pharmaceuticals Market segmentation I:% share, by value,
2009
Table 47: India otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Table 48: India otc pharmaceuticals market share: % share, by value, 2009
Table 49: Cipla Ltd: key facts
Table 50: Cipla Ltd: key financials ($)
Table 51: Cipla Ltd: key financials (Rs.)
Table 52: Cipla Ltd: key financial ratios
Table 53: Johnson & Johnson: key facts
Table 54: Johnson & Johnson: key financials ($)
Table 55: Johnson & Johnson: key financial ratios
Table 56: GlaxoSmithKline Plc: key facts
Table 57: GlaxoSmithKline Plc: key financials ($)
Table 58: GlaxoSmithKline Plc: key financials (£)
Table 59: GlaxoSmithKline Plc: key financial ratios
Table 60: India otc pharmaceuticals market distribution: % share, by value,
2009
Table 61: India OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 62: India size of population (million), 2005-09
Table 63: India gdp (constant 2000 prices, $ billion), 2005-09
Table 64: India gdp (current prices, $ billion), 2005-09
Table 65: India inflation, 2005-09
Table 66: India consumer price index (absolute), 2005-09
Table 67: India exchange rate, 2005-09
Table 68: Russia otc pharmaceuticals market value: $ million, 2005-09
Table 69: Russia otc pharmaceuticals Market segmentation I:% share, by value,
2009
Table 70: Russia otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Table 71: Russia otc pharmaceuticals market share: % share, by value, 2009
Table 72: Ranbaxy Laboratories Limited: key facts
Table 73: Ranbaxy Laboratories Limited: key financials ($)
Table 74: Ranbaxy Laboratories Limited: key financials (Rs.)
Table 75: Ranbaxy Laboratories Limited: key financial ratios
Table 76: Johnson & Johnson: key facts
Table 77: Johnson & Johnson: key financials ($)
Table 78: Johnson & Johnson: key financial ratios
Table 79: Krka: key facts
Table 80: Krka: key financials ($)
Table 81: Krka: key financials (€)
Table 82: Krka: key financial ratios
Table 83: Russia otc pharmaceuticals market distribution: % share, by value,
2009
Table 84: Russia OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 85: Russia size of population (million), 2005-09
Table 86: Russia gdp (constant 2000 prices, $ billion), 2005-09
Table 87: Russia gdp (current prices, $ billion), 2005-09
Table 88: Russia inflation, 2005-09
Table 89: Russia consumer price index (absolute), 2005-09
Table 90: Russia exchange rate, 2005-09
LIST OF FIGURES
Figure 1: BRIC OTC pharmaceuticals industry, revenue($m), 2005-14
Figure 2: BRIC OTC pharmaceuticals industry, revenue($m), 2005-09
Figure 3: BRIC OTC pharmaceuticals industry, revenue($m, 2009-14
Figure 4: Brazil otc pharmaceuticals market value: $ million, 2005-09
Figure 5: Brazil otc pharmaceuticals Market segmentation I:% share, by value,
2009
Figure 6: Brazil otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Figure 7: Brazil otc pharmaceuticals market share: % share, by value, 2009
Figure 8: Forces driving competition in the otc pharmaceuticals market in
Brazil, 2009
Figure 9: Drivers of buyer power in the otc pharmaceuticals market in Brazil,
2009
Figure 10: Drivers of supplier power in the otc pharmaceuticals market in
Brazil, 2009
Figure 11: Factors influencing the likelihood of new entrants in the otc
pharmaceuticals market in Brazil, 2009
Figure 12: Factors influencing the threat of substitutes in the otc
pharmaceuticals market in Brazil, 2009
Figure 13: Drivers of degree of rivalry in the otc pharmaceuticals market in
Brazil, 2009
Figure 14: Johnson & Johnson: revenues & profitability
Figure 15: Johnson & Johnson: assets & liabilities
Figure 16: Sanofi-Aventis: revenues & profitability
Figure 17: Sanofi-Aventis: assets & liabilities
Figure 18: Abbott Laboratories: revenues & profitability
Figure 19: Abbott Laboratories: assets & liabilities
Figure 20: Brazil otc pharmaceuticals market distribution: % share, by value,
2009
Figure 21: Brazil OTC pharmaceuticals market value forecast: $ million,
2009-14
Figure 22: China otc pharmaceuticals market value: $ million, 2005-09
Figure 23: China otc pharmaceuticals Market segmentation I:% share, by value,
2009
Figure 24: China otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Figure 25: China otc pharmaceuticals market share: % share, by value, 2009
Figure 26: Forces driving competition in the otc pharmaceuticals market in
China, 2009
Figure 27: Drivers of buyer power in the otc pharmaceuticals market in China,
2009
Figure 28: Drivers of supplier power in the otc pharmaceuticals market in
China, 2009
Figure 29: Factors influencing the likelihood of new entrants in the otc
pharmaceuticals market in China, 2009
Figure 30: Factors influencing the threat of substitutes in the otc
pharmaceuticals market in China, 2009
Figure 31: Drivers of degree of rivalry in the otc pharmaceuticals market in
China, 2009
Figure 32: Johnson & Johnson: revenues & profitability
Figure 33: Johnson & Johnson: assets & liabilities
Figure 34: Novartis AG: revenues & profitability
Figure 35: Novartis AG: assets & liabilities
Figure 36: China otc pharmaceuticals market distribution: % share, by value,
2009
Figure 37: China OTC pharmaceuticals market value forecast: $ million,
2009-14
Figure 38: India otc pharmaceuticals market value: $ million, 2005-09
Figure 39: India otc pharmaceuticals Market segmentation I:% share, by value,
2009
Figure 40: India otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Figure 41: India otc pharmaceuticals market share: % share, by value, 2009
Figure 42: Forces driving competition in the otc pharmaceuticals market in
India, 2009
Figure 43: Drivers of buyer power in the otc pharmaceuticals market in India,
2009
Figure 44: Drivers of supplier power in the otc pharmaceuticals market in
India, 2009
Figure 45: Factors influencing the likelihood of new entrants in the otc
pharmaceuticals market in India, 2009
Figure 46: Factors influencing the threat of substitutes in the otc
pharmaceuticals market in India, 2009
Figure 47: Drivers of degree of rivalry in the otc pharmaceuticals market in
India, 2009
Figure 48: Cipla Ltd: revenues & profitability
Figure 49: Cipla Ltd: assets & liabilities
Figure 50: Johnson & Johnson: revenues & profitability
Figure 51: Johnson & Johnson: assets & liabilities
Figure 52: GlaxoSmithKline Plc: revenues & profitability
Figure 53: GlaxoSmithKline Plc: assets & liabilities
Figure 54: India otc pharmaceuticals market distribution: % share, by value,
2009
Figure 55: India OTC pharmaceuticals market value forecast: $ million,
2009-14
Figure 56: Russia otc pharmaceuticals market value: $ million, 2005-09
Figure 57: Russia otc pharmaceuticals Market segmentation I:% share, by
value, 2009
Figure 58: Russia otc pharmaceuticals Market segmentation II: % share, by
value, 2009
Figure 59: Russia otc pharmaceuticals market share: % share, by value, 2009
Figure 60: Forces driving competition in the otc pharmaceuticals market in
Russia, 2009
Figure 61: Drivers of buyer power in the otc pharmaceuticals market in
Russia, 2009
Figure 62: Drivers of supplier power in the otc pharmaceuticals market in
Russia, 2009
Figure 63: Factors influencing the likelihood of new entrants in the otc
pharmaceuticals market in Russia, 2009
Figure 64: Factors influencing the threat of substitutes in the otc
pharmaceuticals market in Russia, 2009
Figure 65: Drivers of degree of rivalry in the otc pharmaceuticals market in
Russia, 2009
Figure 66: Ranbaxy Laboratories Limited: revenues & profitability
Figure 67: Ranbaxy Laboratories Limited: assets & liabilities
Figure 68: Johnson & Johnson: revenues & profitability
Figure 69: Johnson & Johnson: assets & liabilities
Figure 70: Krka: revenues & profitability
Figure 71: Krka: assets & liabilities
Figure 72: Russia otc pharmaceuticals market distribution: % share, by value,
2009
Figure 73: Russia OTC pharmaceuticals market value forecast: $ million,
2009-14
